Association of Genetic Variants With Risk of Stroke in Patients With Atrial Fibrillation Off-anticoagulation
Status unconfirmed
Conditions studied: Thromboembolic Events
In brief
Life-long therapy with oral anticoagulants (OAC) is strongly recommended in AF patients receiving left atrial appendage isolation (LAAI) to prevent thromboembolic (TE) events. However, some patients are observed to remain stroke-free while off OACs for years whereas others experience TE events if OAC is discontinued even for a short period of time. Therefore, we aim to evaluate the association of genetic variants (single nucleotide polymorphisms - SNPs) with off-anticoagulation stroke-risk in AF patients.
Key facts
- Study ID
- NCT04115436
- Run by
- Texas Cardiac Arrhythmia Research Foundation
- People needed
- 40
- Starts
- 2019-10-01
- Expected to finish
- 2020-10-01
- Last updated by the study team
- 2019-10-17
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- i. male or female over 18 years of age at the time of enrollment ii. have received LAAI procedure iii. Discontinued OAC for any duration
You may not qualify if…
- i. end-stage renal or liver disease ii. on oral anticoagulation for any other condition iii. pregnant, breastfeeding, or unwilling to provide consent iv. presence of other conditions or abnormalities that in the opinion of the Investigator would compromise the quality of the data
Where it is running
- Texas Cardiac Arrhythmia Institute — Austin, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.